Latest news and press releases about GRI Bio, Inc. (GRI): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Price
| Price | $1.81 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.48 |
| EV / EBITDA | 1.10 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -134.03% |
| Return on Invested Capital | -93.76% |
| Return on Assets | -84.88% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABP · BDRX · CANF · CLDI · CNSP · GNPX · INM
Explore sector: Healthcare · Biotechnology
More sections of GRI: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks